AZ13824374 (AstraZeneca) is an in vitro ATAD2 inhibitor. This article profile discusses ATAD2 as a target and how the molecule was discovered.
2 minute read
Mar. 12, 2022
AZ13824374: An Early ATAD2 Bromodomain-Containing Protein Inhibitor
AZ13824374
in vitro ATAD2 inhibitor Preclinical, oncology from 1.8 million compound HTS and opt. J. Med. Chem. AstraZeneca
Reviewer:
Loading...
